OrphoMed

OrphoMed is a clinical-stage biopharmaceutical company developing first-in-class dimer therapies. Focused on creating a new generation of dimer conjugates with superior therapeutic properties, the company leverages its proprietary dimer platform technology to address issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. The proceeds from this financing will advance the clinical development of OrphoMed’s lead candidate, the novel drug ORP-101, for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).